Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
the same grouping
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Additionally, in vitro, lncRNA HCP5 was confirmed to bind to PTBP1, and sh-lncRNA HCP5 reduced cell viability and enhanced reactive oxygen species. [CONCLUSION] LncRNA HCP5 may promote OVCA progression by inhibiting ferroptosis through interaction with PTBP1, providing new targets in OVCA treatment.
[BACKGROUND] Ovarian cancer (OVCA) is the third most common gynaecological malignancy worldwide.
APA
Chen X, Ren Q, et al. (2025). Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.. Journal of ovarian research, 18(1), 271. https://doi.org/10.1186/s13048-025-01861-6
MLA
Chen X, et al.. "Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.." Journal of ovarian research, vol. 18, no. 1, 2025, pp. 271.
PMID
41257778 ↗
Abstract 한글 요약
[BACKGROUND] Ovarian cancer (OVCA) is the third most common gynaecological malignancy worldwide. Long non-coding RNA (LncRNA) HCP5 and polypyrimidine tract binding protein 1 (PTBP1) involved in regulating tumors, however, with undefined mechanism in OVCA.
[METHODS] After validating lentiviral transfection efficiency, OVCA mouse models were constructed by intraperitoneal injection of ID8-Luc cells for 8 weeks, with sh-lncRNA HCP5, oe-PTBP1, and ferroptosis agonist Erastin treatment. In vivo imaging, tumor metastasis, immunohistochemistry, HE, and TUNEL staining were performed. Human ovarian adenocarcinoma cell SKOV3 cells underwent the same grouping. Interaction between lncRNA HCP5 and PTBP1 was examined using RNA immunoprecipitation and RNA pull-down assay. CCK8, flow cytometry, transmission electron microscopy, biochemical kits, qRT-PCR, and Western blot were performed.
[RESULTS] In OVCA mice, sh-lncRNA HCP5 inhibited tumor growth and increased tumor tissue pathological damage and apoptosis, with lower PTBP1, Ki67, and B-cell lymphoma-2 (Bcl-2) expression, and higher Bcl-2 associated X and caspase-3 expression. Meanwhile, sh-lncRNA HCP5 induced ferroptosis, with reduced glutathione peroxidase 4, glutathione, and recombinant solute carrier family 7, member 11 expression, and elevated malondialdehyde, lipid peroxides, 4-hydroxynonenoic acid, acyl-CoA synthetase long chain family member 4, and transferrin receptor protein expression. These effects were reversed by oe-PTBP1, and Erastin weakened the pro-tumor role of oe-PTBP1, which were also observed in SKOV3 cells. Additionally, in vitro, lncRNA HCP5 was confirmed to bind to PTBP1, and sh-lncRNA HCP5 reduced cell viability and enhanced reactive oxygen species.
[CONCLUSION] LncRNA HCP5 may promote OVCA progression by inhibiting ferroptosis through interaction with PTBP1, providing new targets in OVCA treatment.
[METHODS] After validating lentiviral transfection efficiency, OVCA mouse models were constructed by intraperitoneal injection of ID8-Luc cells for 8 weeks, with sh-lncRNA HCP5, oe-PTBP1, and ferroptosis agonist Erastin treatment. In vivo imaging, tumor metastasis, immunohistochemistry, HE, and TUNEL staining were performed. Human ovarian adenocarcinoma cell SKOV3 cells underwent the same grouping. Interaction between lncRNA HCP5 and PTBP1 was examined using RNA immunoprecipitation and RNA pull-down assay. CCK8, flow cytometry, transmission electron microscopy, biochemical kits, qRT-PCR, and Western blot were performed.
[RESULTS] In OVCA mice, sh-lncRNA HCP5 inhibited tumor growth and increased tumor tissue pathological damage and apoptosis, with lower PTBP1, Ki67, and B-cell lymphoma-2 (Bcl-2) expression, and higher Bcl-2 associated X and caspase-3 expression. Meanwhile, sh-lncRNA HCP5 induced ferroptosis, with reduced glutathione peroxidase 4, glutathione, and recombinant solute carrier family 7, member 11 expression, and elevated malondialdehyde, lipid peroxides, 4-hydroxynonenoic acid, acyl-CoA synthetase long chain family member 4, and transferrin receptor protein expression. These effects were reversed by oe-PTBP1, and Erastin weakened the pro-tumor role of oe-PTBP1, which were also observed in SKOV3 cells. Additionally, in vitro, lncRNA HCP5 was confirmed to bind to PTBP1, and sh-lncRNA HCP5 reduced cell viability and enhanced reactive oxygen species.
[CONCLUSION] LncRNA HCP5 may promote OVCA progression by inhibiting ferroptosis through interaction with PTBP1, providing new targets in OVCA treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Rare fusion transcript in a refractory adult T-cell lymphoblastic lymphoma.
- Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
- Development of a chemiluminescence immunoassay for proGRP in human serum.
- Genetically encoded biosensors in microbes for Tumor targeting.
- Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- A herbal formulation inhibits growth and survival of lung cancer cells through DNA damage and apoptosis - in vitro and in vivo studies.
- Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer.
- Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Dual-responsive semiconducting oligomer/doxorubicin nanoplatform for photoacoustic imaging-guided synergistic chemo-photothermal therapy.